Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/20/2010WO2010055977A1 Method for screening therapeutic agent for neural diseases using gaba b receptors and p-creb
05/20/2010WO2010055974A1 Composition for preventing and treating diabetes and metabolic syndrome disorders containing obovatol and derivatives thereof as active ingredients
05/20/2010WO2010055950A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
05/20/2010WO2010055911A1 Biphenylacetamide derivative
05/20/2010WO2010055833A1 Composition for inhibiting fgf-5, hair tonic, and composition for external use on livestock
05/20/2010WO2010055526A1 A novel polymorph of emtricitabine and a process for preparing of the same
05/20/2010WO2010055513A1 Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same
05/20/2010WO2010055474A2 Antimicrobial compounds and compositions
05/20/2010WO2010055461A1 Method of treating sleep disorders using eplivanserin
05/20/2010WO2010055419A2 A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
05/20/2010WO2010055371A1 Medicament for inhibiting the synthesis of leukotrienes
05/20/2010WO2010055348A1 [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
05/20/2010WO2010055340A1 Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
05/20/2010WO2010055304A2 Pharmaceutical compounds
05/20/2010WO2010055268A1 Novel method for preparing granulates of active principles, and granulates obtained thereof
05/20/2010WO2010055267A1 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
05/20/2010WO2010055260A1 Novel composition based on gamma-hydroxybutyric acid
05/20/2010WO2010055254A1 Histidinol dehydrogenase inhibitors, and use thereof as medicaments
05/20/2010WO2010055170A1 Pyrimidinium derivatives for use in the treatment or prevention of diabetes
05/20/2010WO2010055164A2 Novel inhibitors of flavivirus replication
05/20/2010WO2010055148A2 Dosage of oligonucleotides suitable for the treatment of tumors
05/20/2010WO2010055139A1 Process for manufacturing substituted 3-pyridylmethyl ammonium bromides
05/20/2010WO2010055133A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055132A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055131A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055130A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055129A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055128A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055127A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055126A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055125A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055124A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010WO2010055122A1 Octenidine composition
05/20/2010WO2010055119A2 Pharmaceutical composition comprising pimobendan
05/20/2010WO2010055117A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth
05/20/2010WO2010055083A1 Novel pyrazolone-derivatives and their use as pd4 inhibitors
05/20/2010WO2010055082A2 New crystal form of sunitinib malate
05/20/2010WO2010055081A1 Use of leukotriene inhibitors for treating lung diseases in prematurely born infants
05/20/2010WO2010055072A2 Treating cancer by modulating a mnk
05/20/2010WO2010055028A2 Organic compounds
05/20/2010WO2010055023A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
05/20/2010WO2010055022A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
05/20/2010WO2010055021A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
05/20/2010WO2010055006A1 Naphthylacetic acids used as crth2 antagonists or partial agonists
05/20/2010WO2010055005A1 Naphthylacetic acids
05/20/2010WO2010055004A1 Naphthylacetic acids
05/20/2010WO2010054978A1 Compound useful for treating cellulite
05/20/2010WO2010054968A1 Quinazoline derivatives as nk3 receptor antagonists
05/20/2010WO2010054961A1 Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
05/20/2010WO2010054858A2 Polyvinylpyrrolidone as a therapeutically active compound for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens
05/20/2010WO2010054833A1 Intermediate and oral administrative formats containing lenalidomide
05/20/2010WO2010054826A1 Antisense compositions and methods of making and using same
05/20/2010WO2010054818A1 Nmp-containing extract, a method of its production and uses thereof
05/20/2010WO2010054764A1 Heteroaromatic compounds for use as hif inhibitors
05/20/2010WO2010054763A1 Heterocyclically substituted aryl compounds as hif inhibitors
05/20/2010WO2010054762A1 Aminoalkyl-substituted compounds as hif inhibitors
05/20/2010WO2010054758A1 Synergistic pharmaceutical combination comprising an estrogen receptor antagonist and a progestin
05/20/2010WO2010054606A2 Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments
05/20/2010WO2010054575A1 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof
05/20/2010WO2010054565A1 The water-soluble prodrug of (r)-(-)-bicalutamide, its preparation method and uses thereof
05/20/2010WO2010054533A1 Cyproheptadine hydrochloride cream and preparation method thereof
05/20/2010WO2010054528A1 Quinazoline compounds
05/20/2010WO2010054520A1 Pharmaceutical composition for purifing vein and preparation method thereof
05/20/2010WO2010054512A1 Two types of crystalline of pinocembrin: α and β, their preparation and their use for manufacture of pharmaceutical compositions
05/20/2010WO2010054507A1 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
05/20/2010WO2010054485A1 Organic nutrient salts, methods of preparation and uses
05/20/2010WO2010054470A1 Pumpkin and rose hips weight loss composition
05/20/2010WO2010054469A1 Appetite suppressing weight management composition
05/20/2010WO2010054452A1 New compounds of the pterocarpanquinone family, method for preparing the same, pharmaceutical composition containing the new compounds of the pterocarpanquinone family, uses and therapeutic method
05/20/2010WO2010054438A1 Aryl di-substituted propenone compounds
05/20/2010WO2010036631A3 Sulfonyl compounds which selectively modulate the cb2 receptor
05/20/2010WO2010036630A3 Sulfonyl compounds which selectively modulate the cb2 receptor
05/20/2010WO2010036407A3 Antiviral nucleoside analogs
05/20/2010WO2010033167A3 Anti-thrombin aptamer formulations and methods for use
05/20/2010WO2010030704A3 Antibacterial aminoglycoside analogs
05/20/2010WO2010027567A3 Tricyclic spirocycle derivatives and methods of use thereof
05/20/2010WO2010022017A3 Method and composition for enhancing hematopoietic stem cell mobilization
05/20/2010WO2010020647A3 New method for identifying compounds useful for treating and/or preventing disease-associated with bone loss
05/20/2010WO2010019489A3 Method for making terpene derivatives
05/20/2010WO2010018217A3 Purin derivatives for use in the treatment of fab-related diseases
05/20/2010WO2010017550A3 Lipid compounds for supression of tumorigenesis
05/20/2010WO2010017541A3 Compositions and methods for treatment of neurodegenerative disease
05/20/2010WO2010017094A3 CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
05/20/2010WO2010014933A3 Psma-binding agents and uses thereof
05/20/2010WO2010013078A8 Pyrrolidinyl-alkyl-amide derivatives their preparation and their therapeutic application as ccr3 receptor ligands
05/20/2010WO2010011857A3 Parenteral administration of a glucosamine
05/20/2010WO2010006162A3 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs
05/20/2010WO2010005836A3 Use of rifalazil to treat colonic disorders
05/20/2010WO2009152500A4 Methods and compositions for mediating gene silencing
05/20/2010WO2009140309A3 Boron-containing small molecules
05/20/2010WO2009125117A3 Dermatological composition that can be used in particular for the care and prevention of eschars
05/20/2010WO2009124971A3 Novel compositions and their use
05/20/2010WO2009121623A3 Compounds for treating muscular dystrophy
05/20/2010WO2009117151A3 Vitamin e derivatives and their uses
05/20/2010WO2009102433A3 Compounds with mdr1-inverse activity
05/20/2010WO2009091576A3 Parenteral formulations of dopamine agonists
05/20/2010WO2008121634A3 Nucleoside phosphoramidate prodrugs
05/20/2010US20100125150 salt formation to form N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride; pulmonary disease asthma or chronic obstructive pulmonary disease; administration by inhalation; crystal forms
05/20/2010US20100125131 Gene Encoding A Guanine Nucleotide Exchange Factor And The Gene Product Thereof
05/20/2010US20100125103 Composition for the treatment of diabetes and metabolic syndrome containing obovatol and its synthesized derivatives